Gilder Gagnon Howe & Co. LLC lowered its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 1.7% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,185,380 shares of the biopharmaceutical company’s stock after selling 20,669 shares during the period. Alnylam Pharmaceuticals accounts for about 1.4% of Gilder Gagnon Howe & Co. LLC’s holdings, making the stock its 14th largest position. Gilder Gagnon Howe & Co. LLC owned 1.38% of Alnylam Pharmaceuticals worth $94,546,000 as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. Rockefeller Financial Services Inc. boosted its position in Alnylam Pharmaceuticals by 4,724.4% in the first quarter. Rockefeller Financial Services Inc. now owns 506,223 shares of the biopharmaceutical company’s stock worth $25,944,000 after buying an additional 495,730 shares during the last quarter. Russell Investments Group Ltd. boosted its position in Alnylam Pharmaceuticals by 341.1% in the first quarter. Russell Investments Group Ltd. now owns 277,339 shares of the biopharmaceutical company’s stock worth $14,214,000 after buying an additional 214,470 shares during the last quarter. NBT Bank N A NY bought a new position in Alnylam Pharmaceuticals during the first quarter worth $313,000. First Manhattan Co. bought a new position in Alnylam Pharmaceuticals during the first quarter worth $135,000. Finally, Nationwide Fund Advisors boosted its position in Alnylam Pharmaceuticals by 30.5% in the first quarter. Nationwide Fund Advisors now owns 11,583 shares of the biopharmaceutical company’s stock worth $594,000 after buying an additional 2,707 shares during the last quarter. 88.96% of the stock is owned by hedge funds and other institutional investors.

Shares of Alnylam Pharmaceuticals, Inc. (ALNY) opened at 82.44 on Monday. The firm’s market capitalization is $7.11 billion. Alnylam Pharmaceuticals, Inc. has a one year low of $31.38 and a one year high of $86.92. The stock has a 50 day moving average of $80.45 and a 200-day moving average of $59.96.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Friday, May 5th. The biopharmaceutical company reported ($1.25) earnings per share for the quarter, missing the consensus estimate of ($1.22) by $0.03. The firm had revenue of $19 million during the quarter, compared to analysts’ expectations of $22.91 million. Alnylam Pharmaceuticals had a negative net margin of 705.11% and a negative return on equity of 42.90%. Alnylam Pharmaceuticals’s revenue for the quarter was up 160.3% compared to the same quarter last year. During the same quarter last year, the company posted ($1.21) earnings per share. On average, equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post ($5.19) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This story was originally posted by Daily Political and is owned by of Daily Political. If you are viewing this story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The original version of this story can be viewed at https://www.dailypolitical.com/2017/08/07/alnylam-pharmaceuticals-inc-nasdaqalny-shares-sold-by-gilder-gagnon-howe-co-llc.html.

A number of equities analysts recently weighed in on the stock. Jefferies Group LLC reaffirmed a “buy” rating and set a $102.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Thursday, June 22nd. Chardan Capital reaffirmed a “buy” rating and set a $131.00 price objective (up previously from $110.00) on shares of Alnylam Pharmaceuticals in a research report on Monday, July 10th. Needham & Company LLC reaffirmed a “buy” rating and set a $98.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Monday, July 10th. J P Morgan Chase & Co reaffirmed a “hold” rating on shares of Alnylam Pharmaceuticals in a research report on Monday, June 26th. Finally, Credit Suisse Group increased their price objective on shares of Alnylam Pharmaceuticals from $90.00 to $96.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 27th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $79.79.

In other news, SVP Akshay Vaishnaw sold 43,750 shares of the company’s stock in a transaction on Monday, May 15th. The shares were sold at an average price of $65.00, for a total value of $2,843,750.00. Following the completion of the transaction, the senior vice president now directly owns 43,047 shares in the company, valued at $2,798,055. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Michael Mason sold 9,375 shares of the company’s stock in a transaction on Tuesday, May 16th. The shares were sold at an average price of $70.00, for a total transaction of $656,250.00. Following the completion of the transaction, the vice president now owns 5,625 shares of the company’s stock, valued at $393,750. The disclosure for this sale can be found here. Insiders sold 64,125 shares of company stock valued at $4,325,000 over the last 90 days. Insiders own 4.30% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.